Shopping Cart
- Remove All
- Your shopping cart is currently empty
HKI-357 is an irreversible dual inhibitor of EGFR and ERBB2 (IC50s: 34 nM and 33 nM), effectively suppressing EGFR autophosphorylation (at Y1068), as well as AKT and MAPK phosphorylation.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $72 | In Stock | |
5 mg | $155 | In Stock | |
10 mg | $239 | In Stock | |
25 mg | $487 | In Stock | |
50 mg | $696 | In Stock | |
100 mg | $987 | In Stock | |
1 mL x 10 mM (in DMSO) | $197 | In Stock |
Description | HKI-357 is an irreversible dual inhibitor of EGFR and ERBB2 (IC50s: 34 nM and 33 nM), effectively suppressing EGFR autophosphorylation (at Y1068), as well as AKT and MAPK phosphorylation. |
Targets&IC50 | ErbB2:33 nM, EGFR:34 nM |
In vitro | HKI-357 also is effective in suppressing EGFR autophosphorylation (measured at residue Y1068), and AKT and MAPK phosphorylation in parental NCI-H1650 cells harboring the delE746-A750 EGFR mutation.HKI-357 (0.01-10 μM) is effective in suppressing ligand-induced EGFR autophosphorylation and its downstream signaling, as determined by AKT and MAPK phosphorylation in NCI-H1975 cells. |
Molecular Weight | 574.05 |
Formula | C31H29ClFN5O3 |
Cas No. | 848133-17-5 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | ||||||||||||||||||||||||||||||
Solubility Information | DMSO: 30 mg/mL (52.2 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.